Sanofi-aventis: (NYSE: SNY)
$54.50
0.29 (0.54%)
Volume 1,645,550
May 17 04:00 PM ET
Zacks Rank: 4-Sell 
| #4 |
Full Company Report
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
General Information
SANOFI-AVENTIS
54 RUE LA BOETIE
PARIS, I0 75008
Phone: 33153774400
Fax: 33 1 53 77 43 03
Web: http://www.sanofi-aventis.com
Email: NA
| Industry | LARGE CAP PHARMA |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 03/31/2013 |
| Next EPS Date | 07/25/2013 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 54.21 |
| 52 Week High | 55.77 |
| 52 Week Low | 33.03 |
| Beta | 0.91 |
| 20 Day Moving Average | 1,717,261.00 |
| Target Price Consensus | 54.93 |
% Price Change
| 4 Week | 3.71 |
| 12 Week | 15.15 |
| YTD | 14.41 |
Share Information
| Shares Outstanding (millions) | 2,681.84 |
| Market Capitalization (millions) | 146,160.17 |
| Short Ratio | 0.86 |
| Last Split Date | NA |
% Price Change Relative to S&P 500
| 4 Week | -4.12 |
| 12 Week | 3.75 |
| YTD | 1.26 |
Dividend Information
| Dividend Yield | 2.39% |
| Annual Dividend | $1.30 |
| Payout Ratio | 0.40 |
| Change in Payout Ratio | 0.11 |
| Last Dividend Payout / Amount | NA / $1.30 |
EPS Information
| Current Quarter EPS Consensus Estimate | 0.93 |
| Current Year EPS Consensus Estimate | 3.75 |
| Estimated Long-Term EPS Growth Rate | 6.00 |
| Next EPS Report Date | 07/25/2013 |
Consensus Recommendations
| Current (1=Strong Buy, 5=Strong Sell) | 1.29 |
| 30 Days Ago | 1.22 |
| 60 Days Ago | 1.00 |
| 90 Days Ago | 1.00 |
Fundamental Ratios
P/E
| Current FY Estimate | 14.54 |
| Trailing 12 Months | 15.22 |
| PEG Ratio | 2.42 |
Price Ratios
| Price/Book | 1.95 |
| Price/Cash Flow | 8.38 |
| Price / Sales | 3.27 |
Current Ratio
| 03-31-13 | NA |
| 12-31-12 | 1.64 |
| 09-30-12 | NA |
Net Margin
| 03-31-13 | 11.92 |
| 12-31-12 | 14.16 |
| 09-30-12 | 17.05 |
Inventory Turnover
| 03-31-13 | 1.70 |
| 12-31-12 | 1.72 |
| 09-30-12 | 1.70 |
EPS Growth
| vs. Previous Year | -34.43% |
| vs. Previous Quarter | 2.56% |
ROE
| 03-31-13 | 12.91 |
| 12-31-12 | 14.42 |
| 09-30-12 | 14.84 |
Quick Ratio
| 03-31-13 | NA |
| 12-31-12 | 1.18 |
| 09-30-12 | NA |
Pre-Tax Margin
| 03-31-13 | 14.77 |
| 12-31-12 | 16.34 |
| 09-30-12 | 18.27 |
Debt-to-Equity
| 03-31-13 | NA |
| 12-31-12 | 0.19 |
| 09-30-12 | NA |
Sales Growth
| vs. Previous Year | -5.72% |
| vs. Previous Quarter | -8.21% |
ROA
| 03-31-13 | 7.27 |
| 12-31-12 | 8.12 |
| 09-30-12 | 8.29 |
Operating Margin
| 03-31-13 | 21.14 |
| 12-31-12 | 23.27 |
| 09-30-12 | 24.63 |
Book Value
| 03-31-13 | NA |
| 12-31-12 | 27.91 |
| 09-30-12 | NA |
Debt to Capital
| 03-31-13 | NA |
| 12-31-12 | 15.72 |
| 09-30-12 | NA |
